Archived Monthly Oncology Tumor Boards: Advances in Multidisciplinary Management of Acute Myeloid Leukemia
Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their effective and safe incorporation into clinical practice for the appropriate AML patient subpopulations.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease
Treatment options should be individualized for patients with relapsed/refractory mantle cell lymphoma (MCL). The selection of optimal second-line therapy depends on the age and fitness of the patients as well as the eligibility for transplant. In the absence of standard management, patients with relapsed/refractory MCL, particularly those who are not eligible for transplant, should be referred for participation in prospective clinical trials investigating novel treatment regimens.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing First-Line Therapy for Advanced Stage Classic Hodgkin Lymphoma
Recent studies are demonstrating the utility of novel agents and modifications to existing regimens as viable first-line options in early- and advanced-stage HL. An awareness of the clinical studies evaluating the utility of these treatment modalities will help oncology clinicians determine how to optimally incorporate them into the standard of care for patients and improve patient outcomes.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Treatment Updates in Acute Myeloid Leukemia
Informing clinicians about therapeutic advances and necessary supportive care precautions will aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Acute Myeloid Leukemia: Evidence-Based Guidance on Current Paradigms and New Therapeutic Approaches
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation